NeuroAiD™II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression SINGAPORE, January 22 Moleac is pleased to announce the release of the ATHENE study results,...
Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals SINGAPORE, MAY 2021 Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals. Moleac is dedicated in finding, developing, and commercializing new...
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery SINGAPORE, APRIL 21 Moleac, a biopharmaceutical company based in Singapore, announced the approval by the U.S. Food and Drug...
ESOC 2020: Abstracts on NeuroAiD In November 2020, ESO-WSO provided scientific updates to Health Care Practitioners. During this conference, 4 abstracts on NeuroAiD’s safety and efficacy in post-stroke recovery are presented by international speakers....
World Stroke Day 2020 Stroke remains one of the main cause for disability worldwide. Moleac remains committed to helping patients Reconnect with their loved ones. We always place patients at the center of everything we do, and their journey towards full recovery is...
Highlights from Asia Pacific Stroke Organization (APSC) and World Congress of Neurology (WCN) Scientific Symposia Two scientific symposia were conducted on the 2nd October 2019 and 29th October 2019. Multiple international faculty members shared their perspectives and...
